| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| T-Lymphocytes, Cytotoxic | 110 | 2020 | 504 | 11.410 |
Why?
|
| Herpesvirus 4, Human | 132 | 2025 | 676 | 10.820 |
Why?
|
| Immunotherapy, Adoptive | 106 | 2025 | 832 | 10.510 |
Why?
|
| T-Lymphocytes | 111 | 2025 | 1726 | 9.340 |
Why?
|
| Epstein-Barr Virus Infections | 50 | 2025 | 294 | 6.550 |
Why?
|
| Lymphoma | 30 | 2025 | 323 | 5.080 |
Why?
|
| Receptors, Antigen, T-Cell | 39 | 2025 | 482 | 4.020 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 50 | 2023 | 1203 | 3.340 |
Why?
|
| Immunotherapy | 39 | 2025 | 680 | 3.250 |
Why?
|
| Hodgkin Disease | 31 | 2024 | 292 | 3.070 |
Why?
|
| Viral Matrix Proteins | 24 | 2018 | 109 | 3.070 |
Why?
|
| Lymphoproliferative Disorders | 37 | 2015 | 225 | 2.940 |
Why?
|
| Killer Cells, Natural | 15 | 2023 | 329 | 2.750 |
Why?
|
| Adoptive Transfer | 32 | 2019 | 236 | 2.530 |
Why?
|
| Antigens, Viral | 30 | 2024 | 439 | 2.400 |
Why?
|
| Adenoviridae | 33 | 2019 | 606 | 2.370 |
Why?
|
| Genetic Therapy | 16 | 2018 | 687 | 2.230 |
Why?
|
| Antigens, Neoplasm | 23 | 2021 | 385 | 1.920 |
Why?
|
| Cell- and Tissue-Based Therapy | 14 | 2023 | 164 | 1.900 |
Why?
|
| Virus Diseases | 12 | 2023 | 280 | 1.880 |
Why?
|
| Lymphocyte Activation | 47 | 2019 | 701 | 1.870 |
Why?
|
| Dendritic Cells | 28 | 2017 | 414 | 1.860 |
Why?
|
| Cytomegalovirus | 23 | 2019 | 270 | 1.820 |
Why?
|
| T-Lymphocyte Subsets | 12 | 2017 | 199 | 1.760 |
Why?
|
| Genetic Vectors | 35 | 2019 | 940 | 1.720 |
Why?
|
| Neoplasms | 19 | 2022 | 2790 | 1.640 |
Why?
|
| Neuroblastoma | 12 | 2025 | 526 | 1.610 |
Why?
|
| Antigens, CD19 | 16 | 2019 | 177 | 1.540 |
Why?
|
| Bone Marrow Transplantation | 23 | 2014 | 575 | 1.520 |
Why?
|
| Lymphoma, B-Cell | 10 | 2022 | 141 | 1.440 |
Why?
|
| Herpesviridae Infections | 17 | 2013 | 142 | 1.440 |
Why?
|
| CD4-Positive T-Lymphocytes | 21 | 2020 | 472 | 1.430 |
Why?
|
| Cell Proliferation | 35 | 2019 | 2311 | 1.420 |
Why?
|
| Cell Culture Techniques | 11 | 2016 | 281 | 1.380 |
Why?
|
| Humans | 296 | 2025 | 125269 | 1.350 |
Why?
|
| Epitopes, T-Lymphocyte | 17 | 2020 | 125 | 1.270 |
Why?
|
| Interleukin-7 | 6 | 2023 | 45 | 1.270 |
Why?
|
| Recombinant Fusion Proteins | 27 | 2019 | 772 | 1.260 |
Why?
|
| Cytotoxicity, Immunologic | 30 | 2019 | 264 | 1.250 |
Why?
|
| Graft vs Host Disease | 17 | 2022 | 543 | 1.210 |
Why?
|
| Transduction, Genetic | 22 | 2017 | 289 | 1.200 |
Why?
|
| Tumor Virus Infections | 11 | 2012 | 135 | 1.160 |
Why?
|
| Tumor Microenvironment | 7 | 2023 | 557 | 1.160 |
Why?
|
| Burkitt Lymphoma | 17 | 2011 | 144 | 1.140 |
Why?
|
| Adenoviridae Infections | 8 | 2013 | 71 | 1.120 |
Why?
|
| Cytokines | 20 | 2023 | 1289 | 1.070 |
Why?
|
| CD8-Positive T-Lymphocytes | 18 | 2020 | 397 | 1.050 |
Why?
|
| Antigen-Presenting Cells | 12 | 2014 | 118 | 0.980 |
Why?
|
| Cancer Vaccines | 7 | 2014 | 177 | 0.950 |
Why?
|
| Leukemia, Myeloid, Acute | 8 | 2023 | 537 | 0.920 |
Why?
|
| Animals | 69 | 2024 | 34238 | 0.900 |
Why?
|
| Leukocytes, Mononuclear | 14 | 2023 | 326 | 0.900 |
Why?
|
| Transplantation, Homologous | 23 | 2022 | 667 | 0.890 |
Why?
|
| Immunophenotyping | 26 | 2023 | 329 | 0.880 |
Why?
|
| Tumor Escape | 5 | 2018 | 62 | 0.870 |
Why?
|
| K562 Cells | 9 | 2019 | 95 | 0.860 |
Why?
|
| Mice | 49 | 2024 | 17635 | 0.860 |
Why?
|
| Gene Transfer Techniques | 13 | 2012 | 357 | 0.850 |
Why?
|
| B-Lymphocytes | 20 | 2013 | 535 | 0.830 |
Why?
|
| Musculoskeletal Diseases | 1 | 2023 | 57 | 0.780 |
Why?
|
| Cells, Cultured | 34 | 2020 | 3056 | 0.770 |
Why?
|
| Epstein-Barr Virus Nuclear Antigens | 17 | 2018 | 60 | 0.760 |
Why?
|
| HLA Antigens | 11 | 2023 | 245 | 0.760 |
Why?
|
| Cell Line, Tumor | 28 | 2024 | 3348 | 0.760 |
Why?
|
| Interleukin-12 | 6 | 2015 | 116 | 0.750 |
Why?
|
| Flow Cytometry | 21 | 2017 | 797 | 0.720 |
Why?
|
| Caspase 9 | 9 | 2015 | 75 | 0.710 |
Why?
|
| Combined Modality Therapy | 9 | 2020 | 1243 | 0.700 |
Why?
|
| Immunologic Memory | 9 | 2015 | 190 | 0.690 |
Why?
|
| Ki-1 Antigen | 5 | 2024 | 28 | 0.690 |
Why?
|
| Smallpox | 1 | 2020 | 10 | 0.680 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 7 | 2019 | 783 | 0.680 |
Why?
|
| Smallpox Vaccine | 1 | 2020 | 37 | 0.670 |
Why?
|
| Cell Line | 42 | 2017 | 2756 | 0.660 |
Why?
|
| Interleukin-15 | 9 | 2017 | 93 | 0.660 |
Why?
|
| DNA Transposable Elements | 8 | 2018 | 177 | 0.660 |
Why?
|
| Regenerative Medicine | 2 | 2019 | 31 | 0.660 |
Why?
|
| Immune System Diseases | 2 | 2018 | 46 | 0.640 |
Why?
|
| Interferon-gamma | 8 | 2020 | 505 | 0.620 |
Why?
|
| Glioblastoma | 3 | 2017 | 330 | 0.610 |
Why?
|
| Interleukin-2 | 8 | 2017 | 244 | 0.610 |
Why?
|
| Gangliosides | 4 | 2025 | 72 | 0.610 |
Why?
|
| Antigen Presentation | 15 | 2024 | 104 | 0.610 |
Why?
|
| Oncolytic Viruses | 3 | 2020 | 73 | 0.600 |
Why?
|
| Myeloid-Derived Suppressor Cells | 1 | 2019 | 49 | 0.600 |
Why?
|
| Immunocompromised Host | 8 | 2012 | 294 | 0.580 |
Why?
|
| Microbiota | 1 | 2023 | 389 | 0.570 |
Why?
|
| Receptor, ErbB-2 | 6 | 2017 | 515 | 0.560 |
Why?
|
| DNA Virus Infections | 4 | 2017 | 22 | 0.560 |
Why?
|
| T-Cell Antigen Receptor Specificity | 11 | 2017 | 58 | 0.560 |
Why?
|
| Genes, Transgenic, Suicide | 7 | 2015 | 48 | 0.540 |
Why?
|
| Immunosuppressive Agents | 9 | 2012 | 651 | 0.540 |
Why?
|
| Graft Rejection | 2 | 2019 | 590 | 0.540 |
Why?
|
| Epitopes | 11 | 2020 | 433 | 0.540 |
Why?
|
| Xenograft Model Antitumor Assays | 11 | 2024 | 889 | 0.530 |
Why?
|
| Apoptosis | 11 | 2011 | 1806 | 0.520 |
Why?
|
| Child, Preschool | 48 | 2025 | 14029 | 0.510 |
Why?
|
| Phosphoproteins | 7 | 2012 | 418 | 0.510 |
Why?
|
| Female | 80 | 2025 | 66844 | 0.510 |
Why?
|
| Mice, SCID | 18 | 2015 | 569 | 0.500 |
Why?
|
| Cell Line, Transformed | 13 | 2014 | 168 | 0.500 |
Why?
|
| Receptors, Antigen | 3 | 2014 | 34 | 0.490 |
Why?
|
| Antigens | 6 | 2010 | 156 | 0.480 |
Why?
|
| Adolescent | 48 | 2025 | 19362 | 0.480 |
Why?
|
| Oncogene Proteins, Viral | 2 | 2013 | 58 | 0.480 |
Why?
|
| Recurrence | 15 | 2022 | 1420 | 0.470 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2017 | 210 | 0.470 |
Why?
|
| Leukemia, Myeloid | 2 | 2014 | 85 | 0.470 |
Why?
|
| Male | 82 | 2025 | 61560 | 0.470 |
Why?
|
| Retroviridae | 12 | 2019 | 198 | 0.470 |
Why?
|
| Leukocyte Common Antigens | 5 | 2023 | 91 | 0.460 |
Why?
|
| Diphtheria Toxin | 1 | 2014 | 12 | 0.460 |
Why?
|
| Child | 57 | 2025 | 24431 | 0.450 |
Why?
|
| fas Receptor | 4 | 2017 | 41 | 0.440 |
Why?
|
| Viral Proteins | 10 | 2018 | 347 | 0.440 |
Why?
|
| Vaccinia virus | 4 | 2020 | 52 | 0.440 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 13 | 2016 | 824 | 0.430 |
Why?
|
| Nasopharyngeal Neoplasms | 8 | 2014 | 57 | 0.430 |
Why?
|
| Oncolytic Virotherapy | 5 | 2020 | 85 | 0.430 |
Why?
|
| Leukemia | 8 | 2022 | 373 | 0.420 |
Why?
|
| Chemotaxis, Leukocyte | 2 | 2010 | 63 | 0.420 |
Why?
|
| Lymphocyte Transfusion | 7 | 2007 | 57 | 0.420 |
Why?
|
| Genes, Viral | 9 | 2012 | 185 | 0.420 |
Why?
|
| Transplantation Immunology | 4 | 2006 | 53 | 0.420 |
Why?
|
| Immune System | 1 | 2014 | 90 | 0.420 |
Why?
|
| Papillomavirus E7 Proteins | 1 | 2013 | 19 | 0.410 |
Why?
|
| Factor X | 1 | 2012 | 4 | 0.410 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 4 | 2021 | 42 | 0.400 |
Why?
|
| Human papillomavirus 16 | 1 | 2013 | 50 | 0.400 |
Why?
|
| Virus Replication | 8 | 2020 | 607 | 0.400 |
Why?
|
| Drug Resistance, Neoplasm | 4 | 2014 | 723 | 0.390 |
Why?
|
| Treatment Outcome | 26 | 2025 | 12392 | 0.380 |
Why?
|
| CD28 Antigens | 9 | 2017 | 81 | 0.380 |
Why?
|
| Adult | 46 | 2025 | 29652 | 0.380 |
Why?
|
| Coculture Techniques | 9 | 2019 | 227 | 0.380 |
Why?
|
| Cell Survival | 8 | 2017 | 813 | 0.370 |
Why?
|
| Genetic Markers | 10 | 1998 | 603 | 0.370 |
Why?
|
| Amino Acid Sequence | 14 | 2020 | 2714 | 0.370 |
Why?
|
| Brain Neoplasms | 5 | 2017 | 1216 | 0.370 |
Why?
|
| Postoperative Complications | 11 | 2012 | 3075 | 0.360 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2014 | 128 | 0.360 |
Why?
|
| Transgenes | 9 | 2018 | 336 | 0.360 |
Why?
|
| Virus Latency | 5 | 2024 | 60 | 0.360 |
Why?
|
| Stem Cells | 2 | 2015 | 707 | 0.360 |
Why?
|
| T-Lymphocytes, Regulatory | 5 | 2012 | 216 | 0.360 |
Why?
|
| DNA, Viral | 17 | 2011 | 480 | 0.350 |
Why?
|
| Lymphoma, Non-Hodgkin | 6 | 2018 | 164 | 0.350 |
Why?
|
| Interleukin-1 Receptor-Associated Kinases | 1 | 2010 | 21 | 0.350 |
Why?
|
| Young Adult | 19 | 2024 | 9056 | 0.340 |
Why?
|
| Immunity, Cellular | 10 | 2023 | 206 | 0.340 |
Why?
|
| Blotting, Western | 7 | 2015 | 1102 | 0.340 |
Why?
|
| Immunity, Innate | 1 | 2012 | 372 | 0.330 |
Why?
|
| Cytomegalovirus Infections | 5 | 2019 | 221 | 0.330 |
Why?
|
| Sirolimus | 1 | 2011 | 227 | 0.330 |
Why?
|
| Mice, Inbred NOD | 8 | 2017 | 286 | 0.330 |
Why?
|
| Middle Aged | 34 | 2025 | 26943 | 0.320 |
Why?
|
| NF-kappa B | 2 | 2017 | 459 | 0.320 |
Why?
|
| CD3 Complex | 6 | 2017 | 91 | 0.310 |
Why?
|
| Histocompatibility Antigens Class I | 4 | 2019 | 97 | 0.310 |
Why?
|
| Time Factors | 15 | 2018 | 6339 | 0.310 |
Why?
|
| Hematologic Neoplasms | 3 | 2022 | 285 | 0.310 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2011 | 429 | 0.310 |
Why?
|
| Neoplasm Proteins | 4 | 2021 | 667 | 0.300 |
Why?
|
| Fetal Blood | 5 | 2011 | 177 | 0.300 |
Why?
|
| Capsid Proteins | 3 | 2007 | 184 | 0.300 |
Why?
|
| Transfection | 11 | 2013 | 1069 | 0.290 |
Why?
|
| Repressor Proteins | 1 | 2013 | 813 | 0.290 |
Why?
|
| Vaccination | 5 | 2023 | 964 | 0.290 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 3 | 2016 | 183 | 0.290 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2010 | 489 | 0.290 |
Why?
|
| CD27 Ligand | 2 | 2021 | 5 | 0.280 |
Why?
|
| Tumor Cells, Cultured | 9 | 2011 | 1065 | 0.280 |
Why?
|
| Cross Reactions | 3 | 2004 | 192 | 0.280 |
Why?
|
| Fluorescent Dyes | 1 | 2008 | 262 | 0.280 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 4 | 2014 | 97 | 0.270 |
Why?
|
| Stem Cell Transplantation | 7 | 2020 | 237 | 0.270 |
Why?
|
| Gene Expression | 12 | 2018 | 1560 | 0.270 |
Why?
|
| Peptides | 6 | 2024 | 811 | 0.270 |
Why?
|
| Antineoplastic Agents | 8 | 2022 | 1691 | 0.270 |
Why?
|
| Single-Chain Antibodies | 2 | 2021 | 44 | 0.260 |
Why?
|
| Multiple Myeloma | 3 | 2020 | 161 | 0.260 |
Why?
|
| Tissue Transplantation | 2 | 2005 | 11 | 0.260 |
Why?
|
| DNA Viruses | 3 | 2017 | 33 | 0.260 |
Why?
|
| Virus Activation | 6 | 2018 | 87 | 0.250 |
Why?
|
| Cell Transformation, Viral | 6 | 2012 | 106 | 0.250 |
Why?
|
| Lymphocyte Depletion | 5 | 2020 | 123 | 0.250 |
Why?
|
| Receptors, OX40 | 2 | 2024 | 7 | 0.250 |
Why?
|
| 4-1BB Ligand | 2 | 2017 | 11 | 0.240 |
Why?
|
| Influenza, Human | 1 | 2011 | 662 | 0.240 |
Why?
|
| HIV-1 | 4 | 2018 | 465 | 0.240 |
Why?
|
| Molecular Sequence Data | 13 | 2005 | 3892 | 0.240 |
Why?
|
| Antibody Formation | 2 | 2025 | 266 | 0.240 |
Why?
|
| Neoplasm Transplantation | 3 | 2023 | 376 | 0.240 |
Why?
|
| Neoplasms, Experimental | 3 | 2015 | 211 | 0.240 |
Why?
|
| Lymphocyte Count | 3 | 2017 | 118 | 0.240 |
Why?
|
| Lymphoma, T-Cell | 2 | 2018 | 64 | 0.240 |
Why?
|
| Cell Separation | 6 | 2012 | 229 | 0.230 |
Why?
|
| Signal Transduction | 6 | 2018 | 4534 | 0.230 |
Why?
|
| Interleukin-10 | 3 | 1997 | 174 | 0.230 |
Why?
|
| Hematopoietic Stem Cells | 4 | 2016 | 541 | 0.230 |
Why?
|
| Antibodies, Viral | 5 | 2025 | 1154 | 0.230 |
Why?
|
| Blood Component Removal | 2 | 2016 | 32 | 0.220 |
Why?
|
| Tissue Donors | 6 | 2020 | 494 | 0.220 |
Why?
|
| Transplantation, Autologous | 6 | 2018 | 300 | 0.220 |
Why?
|
| Proteome | 1 | 2025 | 243 | 0.210 |
Why?
|
| Neoplasm Recurrence, Local | 6 | 2018 | 1140 | 0.200 |
Why?
|
| Cell Differentiation | 7 | 2017 | 1898 | 0.200 |
Why?
|
| Immunodominant Epitopes | 2 | 2012 | 50 | 0.200 |
Why?
|
| HLA-A Antigens | 5 | 2011 | 35 | 0.200 |
Why?
|
| Heterografts | 1 | 2023 | 173 | 0.200 |
Why?
|
| Infant | 20 | 2025 | 12517 | 0.200 |
Why?
|
| Tumor Necrosis Factor Receptor Superfamily, Member 9 | 2 | 2024 | 25 | 0.200 |
Why?
|
| Remission Induction | 5 | 2016 | 300 | 0.200 |
Why?
|
| Immunoglobulin kappa-Chains | 2 | 2016 | 30 | 0.200 |
Why?
|
| CD4 Antigens | 1 | 2002 | 57 | 0.190 |
Why?
|
| Receptors, Interleukin-7 | 2 | 2014 | 21 | 0.190 |
Why?
|
| Lymphoma, Extranodal NK-T-Cell | 1 | 2021 | 3 | 0.190 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2024 | 197 | 0.190 |
Why?
|
| Cell Engineering | 2 | 2018 | 21 | 0.180 |
Why?
|
| Financing, Government | 1 | 2021 | 30 | 0.180 |
Why?
|
| Lymphoma, Large-Cell, Anaplastic | 3 | 2017 | 46 | 0.180 |
Why?
|
| Osteosarcoma | 3 | 2015 | 255 | 0.180 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2023 | 367 | 0.180 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 2 | 2019 | 61 | 0.180 |
Why?
|
| Viral Load | 8 | 2019 | 387 | 0.180 |
Why?
|
| Viral Structural Proteins | 1 | 2001 | 48 | 0.180 |
Why?
|
| Receptors, Transforming Growth Factor beta | 3 | 2008 | 108 | 0.180 |
Why?
|
| Adenoviruses, Human | 4 | 2017 | 81 | 0.180 |
Why?
|
| Interleukin-7 Receptor alpha Subunit | 2 | 2024 | 20 | 0.180 |
Why?
|
| Antigens, CD20 | 4 | 2006 | 37 | 0.170 |
Why?
|
| Bone Neoplasms | 3 | 2015 | 426 | 0.170 |
Why?
|
| Aged | 15 | 2025 | 19881 | 0.170 |
Why?
|
| Phylogeny | 1 | 2023 | 696 | 0.170 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 6 | 2010 | 1290 | 0.170 |
Why?
|
| Cell Transplantation | 3 | 2017 | 45 | 0.170 |
Why?
|
| Base Sequence | 8 | 2015 | 3103 | 0.170 |
Why?
|
| Measles virus | 1 | 2020 | 16 | 0.170 |
Why?
|
| HIV Infections | 3 | 2018 | 1899 | 0.170 |
Why?
|
| Lymphocytes | 5 | 2023 | 410 | 0.170 |
Why?
|
| Organ Transplantation | 2 | 2001 | 168 | 0.170 |
Why?
|
| HEK293 Cells | 6 | 2021 | 733 | 0.160 |
Why?
|
| Liver Transplantation | 5 | 2011 | 1037 | 0.160 |
Why?
|
| Virion | 1 | 2020 | 147 | 0.160 |
Why?
|
| beta 2-Microglobulin | 1 | 2019 | 35 | 0.160 |
Why?
|
| Mutant Chimeric Proteins | 2 | 2017 | 16 | 0.160 |
Why?
|
| Leukemia, B-Cell | 3 | 2010 | 26 | 0.160 |
Why?
|
| Antiretroviral Therapy, Highly Active | 2 | 2018 | 267 | 0.160 |
Why?
|
| Carcinoma | 3 | 2014 | 287 | 0.160 |
Why?
|
| Viruses | 2 | 2014 | 122 | 0.160 |
Why?
|
| HLA-A2 Antigen | 5 | 2011 | 26 | 0.160 |
Why?
|
| Salvage Therapy | 1 | 2021 | 192 | 0.160 |
Why?
|
| Antibodies, Monoclonal | 9 | 2008 | 1033 | 0.160 |
Why?
|
| Cell Movement | 4 | 2012 | 847 | 0.160 |
Why?
|
| Plasmids | 7 | 2015 | 513 | 0.160 |
Why?
|
| Gene Expression Regulation, Leukemic | 2 | 2017 | 63 | 0.160 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily K | 1 | 2019 | 19 | 0.160 |
Why?
|
| Bacteria | 1 | 2023 | 484 | 0.160 |
Why?
|
| Promoter Regions, Genetic | 4 | 1992 | 1328 | 0.150 |
Why?
|
| Melanoma | 3 | 2015 | 942 | 0.150 |
Why?
|
| Chemokines | 1 | 2019 | 133 | 0.150 |
Why?
|
| Protein Domains | 1 | 2019 | 236 | 0.150 |
Why?
|
| Neoplastic Stem Cells | 4 | 2011 | 294 | 0.150 |
Why?
|
| Transforming Growth Factor beta | 5 | 2010 | 461 | 0.150 |
Why?
|
| Adenovirus Infections, Human | 2 | 2009 | 50 | 0.150 |
Why?
|
| Phenotype | 10 | 2018 | 4262 | 0.140 |
Why?
|
| Interleukin-1 | 1 | 2018 | 142 | 0.140 |
Why?
|
| Macrophages | 2 | 2018 | 626 | 0.140 |
Why?
|
| Leukemia-Lymphoma, Adult T-Cell | 1 | 2017 | 30 | 0.140 |
Why?
|
| Polymerase Chain Reaction | 8 | 2015 | 1586 | 0.140 |
Why?
|
| Receptors, Cytokine | 1 | 2017 | 68 | 0.140 |
Why?
|
| Ligands | 1 | 2019 | 539 | 0.140 |
Why?
|
| Erythropoietin | 1 | 2018 | 105 | 0.140 |
Why?
|
| RNA, Small Interfering | 3 | 2010 | 663 | 0.140 |
Why?
|
| Lectins, C-Type | 1 | 2017 | 70 | 0.140 |
Why?
|
| CD8 Antigens | 2 | 2015 | 41 | 0.140 |
Why?
|
| Lymphocyte Subsets | 1 | 2017 | 38 | 0.130 |
Why?
|
| Mucin-1 | 2 | 2013 | 35 | 0.130 |
Why?
|
| Immunologic Factors | 1 | 2018 | 174 | 0.130 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2015 | 1056 | 0.130 |
Why?
|
| Cytotoxicity Tests, Immunologic | 4 | 2007 | 23 | 0.130 |
Why?
|
| Osteolysis | 1 | 1996 | 9 | 0.130 |
Why?
|
| Vaccines, Attenuated | 1 | 2017 | 175 | 0.130 |
Why?
|
| Herpesvirus 6, Human | 2 | 2017 | 58 | 0.130 |
Why?
|
| RNA, Messenger | 6 | 2010 | 2820 | 0.130 |
Why?
|
| Spleen | 2 | 2015 | 281 | 0.130 |
Why?
|
| Clinical Trials as Topic | 4 | 2012 | 1101 | 0.130 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 4 | 2010 | 63 | 0.130 |
Why?
|
| Disease-Free Survival | 4 | 2013 | 897 | 0.130 |
Why?
|
| Feeder Cells | 1 | 2016 | 9 | 0.130 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2017 | 128 | 0.130 |
Why?
|
| Follow-Up Studies | 7 | 2022 | 5180 | 0.130 |
Why?
|
| Peptide Fragments | 5 | 2011 | 780 | 0.130 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2017 | 115 | 0.120 |
Why?
|
| Cell Division | 4 | 2003 | 781 | 0.120 |
Why?
|
| Tacrolimus | 2 | 2009 | 98 | 0.120 |
Why?
|
| Receptors, CCR7 | 1 | 2015 | 20 | 0.120 |
Why?
|
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2015 | 15 | 0.120 |
Why?
|
| Blood Donors | 3 | 2011 | 62 | 0.120 |
Why?
|
| Models, Biological | 4 | 2012 | 1460 | 0.120 |
Why?
|
| Azacitidine | 2 | 2013 | 52 | 0.120 |
Why?
|
| HIV Antigens | 1 | 2014 | 12 | 0.120 |
Why?
|
| Gamma Rays | 1 | 2014 | 50 | 0.120 |
Why?
|
| Chromosomes, Artificial, Bacterial | 1 | 2015 | 93 | 0.120 |
Why?
|
| Lentivirus | 4 | 2017 | 82 | 0.120 |
Why?
|
| Graft vs Leukemia Effect | 1 | 2014 | 30 | 0.110 |
Why?
|
| Gene Editing | 1 | 2016 | 187 | 0.110 |
Why?
|
| Cell Death | 3 | 2017 | 239 | 0.110 |
Why?
|
| Interleukin-4 Receptor alpha Subunit | 1 | 2014 | 9 | 0.110 |
Why?
|
| Prostatic Neoplasms | 2 | 2013 | 1547 | 0.110 |
Why?
|
| Caspases | 2 | 2005 | 162 | 0.110 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2020 | 1251 | 0.110 |
Why?
|
| CRISPR-Cas Systems | 1 | 2016 | 254 | 0.110 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2016 | 205 | 0.110 |
Why?
|
| Research Support as Topic | 1 | 2014 | 63 | 0.110 |
Why?
|
| Aspergillosis, Allergic Bronchopulmonary | 1 | 2013 | 19 | 0.110 |
Why?
|
| Adult Stem Cells | 1 | 2014 | 54 | 0.110 |
Why?
|
| Th1 Cells | 2 | 2013 | 153 | 0.110 |
Why?
|
| Risk Factors | 9 | 2015 | 10319 | 0.110 |
Why?
|
| Tacrolimus Binding Proteins | 2 | 2011 | 66 | 0.110 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2017 | 1697 | 0.110 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2014 | 118 | 0.100 |
Why?
|
| Granulomatous Disease, Chronic | 1 | 2013 | 66 | 0.100 |
Why?
|
| Flutamide | 1 | 2013 | 26 | 0.100 |
Why?
|
| Program Development | 1 | 2014 | 185 | 0.100 |
Why?
|
| Green Fluorescent Proteins | 4 | 2015 | 388 | 0.100 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 2011 | 183 | 0.100 |
Why?
|
| Sarcoma | 1 | 2015 | 182 | 0.100 |
Why?
|
| Cyclophosphamide | 3 | 2020 | 417 | 0.100 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2014 | 174 | 0.100 |
Why?
|
| Roseolovirus Infections | 1 | 2012 | 33 | 0.100 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2017 | 1894 | 0.100 |
Why?
|
| Monocytes | 3 | 2012 | 345 | 0.100 |
Why?
|
| Receptors, Chemokine | 1 | 2012 | 44 | 0.100 |
Why?
|
| Cryopreservation | 1 | 2012 | 74 | 0.100 |
Why?
|
| Disease Models, Animal | 6 | 2024 | 4396 | 0.100 |
Why?
|
| Mice, Inbred BALB C | 3 | 2010 | 997 | 0.100 |
Why?
|
| Immunohistochemistry | 3 | 2015 | 1693 | 0.090 |
Why?
|
| Breast Neoplasms | 1 | 2024 | 2513 | 0.090 |
Why?
|
| Feasibility Studies | 6 | 2016 | 762 | 0.090 |
Why?
|
| Gene Expression Regulation, Viral | 1 | 1992 | 131 | 0.090 |
Why?
|
| Survival Rate | 3 | 2013 | 2062 | 0.090 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2012 | 204 | 0.090 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2013 | 257 | 0.090 |
Why?
|
| Chills | 1 | 2010 | 6 | 0.090 |
Why?
|
| Home Infusion Therapy | 1 | 2010 | 6 | 0.090 |
Why?
|
| Cerebral Revascularization | 1 | 1991 | 21 | 0.090 |
Why?
|
| B7-1 Antigen | 2 | 2007 | 11 | 0.090 |
Why?
|
| Neomycin | 3 | 2000 | 37 | 0.090 |
Why?
|
| Pancreatic Neoplasms | 1 | 2017 | 691 | 0.090 |
Why?
|
| Receptors, CCR2 | 1 | 2010 | 25 | 0.090 |
Why?
|
| Postoperative Nausea and Vomiting | 1 | 2010 | 14 | 0.090 |
Why?
|
| Wnt Proteins | 1 | 2011 | 194 | 0.090 |
Why?
|
| Drugs, Investigational | 1 | 2010 | 22 | 0.090 |
Why?
|
| Enzyme Induction | 2 | 2014 | 104 | 0.090 |
Why?
|
| Membrane Glycoproteins | 3 | 2013 | 411 | 0.090 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2013 | 165 | 0.090 |
Why?
|
| Moyamoya Disease | 1 | 1991 | 38 | 0.090 |
Why?
|
| Mice, Inbred C57BL | 5 | 2013 | 4406 | 0.090 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2014 | 541 | 0.080 |
Why?
|
| BK Virus | 2 | 2017 | 60 | 0.080 |
Why?
|
| Receptors, Virus | 2 | 2010 | 107 | 0.080 |
Why?
|
| Bone Marrow Purging | 5 | 1996 | 34 | 0.080 |
Why?
|
| Antibody Specificity | 2 | 2001 | 204 | 0.080 |
Why?
|
| Prognosis | 7 | 2021 | 4646 | 0.080 |
Why?
|
| Sequence Analysis, DNA | 2 | 2015 | 1756 | 0.080 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2015 | 880 | 0.080 |
Why?
|
| Organic Chemicals | 3 | 2015 | 59 | 0.080 |
Why?
|
| Tumor Burden | 1 | 2010 | 230 | 0.080 |
Why?
|
| Tacrolimus Binding Protein 1A | 1 | 2009 | 20 | 0.080 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2013 | 237 | 0.080 |
Why?
|
| Reproducibility of Results | 2 | 2010 | 2894 | 0.080 |
Why?
|
| Immune Tolerance | 3 | 2007 | 144 | 0.080 |
Why?
|
| Receptors, CCR4 | 1 | 2009 | 7 | 0.080 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 1 | 2010 | 86 | 0.080 |
Why?
|
| Antigens, Surface | 3 | 1986 | 117 | 0.080 |
Why?
|
| Immunoglobulin G | 3 | 2025 | 777 | 0.080 |
Why?
|
| Peptide Library | 2 | 2011 | 57 | 0.080 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2012 | 468 | 0.080 |
Why?
|
| Recoverin | 1 | 2008 | 10 | 0.080 |
Why?
|
| Molecular Targeted Therapy | 3 | 2017 | 361 | 0.080 |
Why?
|
| Transplantation Conditioning | 3 | 2017 | 325 | 0.080 |
Why?
|
| Papillomavirus Infections | 1 | 2013 | 296 | 0.080 |
Why?
|
| Interleukins | 1 | 2009 | 120 | 0.080 |
Why?
|
| Spectrometry, Fluorescence | 1 | 2008 | 88 | 0.080 |
Why?
|
| Biological Specimen Banks | 1 | 2008 | 51 | 0.080 |
Why?
|
| Down-Regulation | 2 | 2015 | 699 | 0.070 |
Why?
|
| Recombinant Proteins | 4 | 2003 | 1399 | 0.070 |
Why?
|
| Gene Knockdown Techniques | 1 | 2009 | 359 | 0.070 |
Why?
|
| Transplantation, Heterologous | 3 | 2014 | 256 | 0.070 |
Why?
|
| Genes | 1 | 1989 | 447 | 0.070 |
Why?
|
| Brain Ischemia | 1 | 1991 | 265 | 0.070 |
Why?
|
| Histocompatibility Antigens Class II | 3 | 2003 | 84 | 0.070 |
Why?
|
| Fever | 1 | 2010 | 299 | 0.070 |
Why?
|
| Vidarabine | 2 | 2020 | 79 | 0.070 |
Why?
|
| Genome, Human | 1 | 2015 | 1273 | 0.070 |
Why?
|
| Organisms, Genetically Modified | 1 | 2007 | 11 | 0.070 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2008 | 141 | 0.070 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2014 | 930 | 0.070 |
Why?
|
| Spectroscopy, Near-Infrared | 1 | 2008 | 145 | 0.070 |
Why?
|
| In Vitro Techniques | 3 | 2010 | 983 | 0.070 |
Why?
|
| MART-1 Antigen | 1 | 2007 | 14 | 0.070 |
Why?
|
| Herpesvirus 3, Human | 1 | 2007 | 26 | 0.070 |
Why?
|
| Conserved Sequence | 2 | 2007 | 291 | 0.070 |
Why?
|
| B7-2 Antigen | 1 | 2007 | 15 | 0.070 |
Why?
|
| Viral Vaccines | 1 | 2010 | 337 | 0.070 |
Why?
|
| Optics and Photonics | 1 | 2008 | 139 | 0.070 |
Why?
|
| Calcium Phosphates | 1 | 2007 | 8 | 0.070 |
Why?
|
| Integrins | 2 | 2023 | 99 | 0.070 |
Why?
|
| Alleles | 4 | 2004 | 1614 | 0.070 |
Why?
|
| Gene Deletion | 3 | 2016 | 789 | 0.070 |
Why?
|
| Sensitivity and Specificity | 2 | 2005 | 2058 | 0.070 |
Why?
|
| Haplotypes | 3 | 2015 | 522 | 0.070 |
Why?
|
| Myeloid Cells | 2 | 2017 | 102 | 0.070 |
Why?
|
| Gene Expression Regulation | 4 | 1989 | 2522 | 0.070 |
Why?
|
| Nerve Tissue Proteins | 1 | 2013 | 1113 | 0.070 |
Why?
|
| Disease Progression | 3 | 2017 | 2067 | 0.070 |
Why?
|
| HLA-DR Antigens | 2 | 2003 | 77 | 0.070 |
Why?
|
| Sequence Homology, Amino Acid | 2 | 2001 | 658 | 0.060 |
Why?
|
| Liver Neoplasms | 2 | 2014 | 1314 | 0.060 |
Why?
|
| Cell Communication | 1 | 2007 | 167 | 0.060 |
Why?
|
| Cation Transport Proteins | 1 | 2006 | 93 | 0.060 |
Why?
|
| Receptors, Interleukin-2 | 2 | 2003 | 43 | 0.060 |
Why?
|
| Genetic Engineering | 3 | 2014 | 159 | 0.060 |
Why?
|
| Chromium | 1 | 2005 | 7 | 0.060 |
Why?
|
| Lymph Nodes | 1 | 2007 | 379 | 0.060 |
Why?
|
| Rituximab | 4 | 2010 | 159 | 0.060 |
Why?
|
| Fas Ligand Protein | 1 | 2005 | 33 | 0.060 |
Why?
|
| Texas | 1 | 2013 | 3588 | 0.060 |
Why?
|
| Immunologic Surveillance | 1 | 1985 | 15 | 0.060 |
Why?
|
| Jurkat Cells | 1 | 2005 | 92 | 0.060 |
Why?
|
| Caspase 3 | 1 | 2005 | 132 | 0.060 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2005 | 61 | 0.060 |
Why?
|
| COS Cells | 1 | 2005 | 274 | 0.060 |
Why?
|
| Ovalbumin | 2 | 2018 | 319 | 0.060 |
Why?
|
| Immunity | 2 | 2004 | 192 | 0.060 |
Why?
|
| United States | 6 | 2021 | 10918 | 0.060 |
Why?
|
| Gammaretrovirus | 2 | 2017 | 5 | 0.060 |
Why?
|
| Luminescent Proteins | 2 | 2001 | 156 | 0.060 |
Why?
|
| Epitope Mapping | 1 | 2004 | 80 | 0.060 |
Why?
|
| Biopsy | 4 | 2006 | 1238 | 0.060 |
Why?
|
| Aspergillus fumigatus | 2 | 2014 | 43 | 0.060 |
Why?
|
| HLA-B Antigens | 1 | 2024 | 28 | 0.050 |
Why?
|
| Mice, Transgenic | 4 | 2014 | 2397 | 0.050 |
Why?
|
| Hydroxamic Acids | 2 | 2015 | 56 | 0.050 |
Why?
|
| Medulloblastoma | 1 | 2007 | 326 | 0.050 |
Why?
|
| Transposases | 2 | 2015 | 40 | 0.050 |
Why?
|
| Infectious Mononucleosis | 2 | 1997 | 15 | 0.050 |
Why?
|
| Sarcoma, Ewing | 2 | 2015 | 110 | 0.050 |
Why?
|
| Trans-Activators | 3 | 2018 | 798 | 0.050 |
Why?
|
| Infusions, Intravenous | 2 | 2010 | 555 | 0.050 |
Why?
|
| DNA-Binding Proteins | 5 | 2003 | 2048 | 0.050 |
Why?
|
| Neoplasm Grading | 1 | 2024 | 272 | 0.050 |
Why?
|
| JC Virus | 1 | 2003 | 30 | 0.050 |
Why?
|
| HLA-DP Antigens | 1 | 2002 | 5 | 0.050 |
Why?
|
| Virus Shedding | 1 | 2003 | 80 | 0.050 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2015 | 506 | 0.050 |
Why?
|
| Thymidine Kinase | 1 | 2003 | 95 | 0.050 |
Why?
|
| Telomerase | 1 | 2003 | 160 | 0.050 |
Why?
|
| Antiviral Agents | 2 | 2005 | 753 | 0.050 |
Why?
|
| Mice, Knockout | 4 | 2013 | 3745 | 0.050 |
Why?
|
| Transplants | 1 | 2003 | 35 | 0.050 |
Why?
|
| Mutation | 5 | 2024 | 5845 | 0.050 |
Why?
|
| Culture Media, Conditioned | 1 | 2002 | 81 | 0.050 |
Why?
|
| Safety | 3 | 2006 | 217 | 0.050 |
Why?
|
| THP-1 Cells | 1 | 2021 | 23 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2022 | 80 | 0.050 |
Why?
|
| Carrier State | 1 | 2002 | 76 | 0.050 |
Why?
|
| HLA-A11 Antigen | 1 | 2001 | 3 | 0.050 |
Why?
|
| Government Regulation | 1 | 2021 | 41 | 0.050 |
Why?
|
| Histocompatibility Testing | 3 | 2009 | 148 | 0.050 |
Why?
|
| CD40 Ligand | 1 | 2001 | 64 | 0.050 |
Why?
|
| Positron-Emission Tomography | 2 | 2015 | 306 | 0.050 |
Why?
|
| HeLa Cells | 2 | 2015 | 806 | 0.050 |
Why?
|
| Cyclosporine | 1 | 2001 | 147 | 0.040 |
Why?
|
| Bone Marrow Cells | 2 | 2007 | 264 | 0.040 |
Why?
|
| Thymus Gland | 1 | 2001 | 100 | 0.040 |
Why?
|
| Academies and Institutes | 1 | 2021 | 83 | 0.040 |
Why?
|
| Bendamustine Hydrochloride | 1 | 2020 | 14 | 0.040 |
Why?
|
| Immunoenzyme Techniques | 2 | 2011 | 258 | 0.040 |
Why?
|
| Chronic Disease | 4 | 2011 | 1201 | 0.040 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2000 | 80 | 0.040 |
Why?
|
| Receptors, IgG | 1 | 2000 | 59 | 0.040 |
Why?
|
| Kidney Transplantation | 1 | 2006 | 647 | 0.040 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2001 | 100 | 0.040 |
Why?
|
| Forkhead Transcription Factors | 2 | 2012 | 354 | 0.040 |
Why?
|
| Neoplasm Metastasis | 2 | 2015 | 686 | 0.040 |
Why?
|
| Receptors, Tumor Necrosis Factor | 2 | 2014 | 70 | 0.040 |
Why?
|
| Up-Regulation | 2 | 2014 | 867 | 0.040 |
Why?
|
| DiGeorge Syndrome | 1 | 2001 | 80 | 0.040 |
Why?
|
| Cellular Senescence | 1 | 2001 | 161 | 0.040 |
Why?
|
| Fatal Outcome | 1 | 2001 | 359 | 0.040 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2008 | 817 | 0.040 |
Why?
|
| Fibroblasts | 1 | 2004 | 888 | 0.040 |
Why?
|
| Symporters | 1 | 2020 | 70 | 0.040 |
Why?
|
| Nuclear Proteins | 1 | 2006 | 1265 | 0.040 |
Why?
|
| Glioma | 1 | 2024 | 492 | 0.040 |
Why?
|
| Sequence Alignment | 1 | 2001 | 620 | 0.040 |
Why?
|
| Blotting, Southern | 2 | 2000 | 215 | 0.040 |
Why?
|
| Cell Cycle | 1 | 2001 | 617 | 0.040 |
Why?
|
| Sequence Deletion | 1 | 2001 | 525 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2015 | 2107 | 0.040 |
Why?
|
| Graft vs Tumor Effect | 1 | 1998 | 7 | 0.040 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2018 | 78 | 0.040 |
Why?
|
| Enhancer Elements, Genetic | 2 | 1990 | 296 | 0.040 |
Why?
|
| Age Factors | 3 | 2011 | 2825 | 0.040 |
Why?
|
| Immunization | 1 | 1999 | 308 | 0.040 |
Why?
|
| Chromosome Deletion | 3 | 1990 | 647 | 0.040 |
Why?
|
| Immunoconjugates | 1 | 2017 | 38 | 0.030 |
Why?
|
| Immunoglobulins | 3 | 2007 | 173 | 0.030 |
Why?
|
| Protein Structure, Tertiary | 2 | 2011 | 767 | 0.030 |
Why?
|
| Neoplasm, Residual | 2 | 2011 | 122 | 0.030 |
Why?
|
| Autoimmune Diseases | 1 | 1999 | 251 | 0.030 |
Why?
|
| Interleukin-4 | 1 | 2017 | 140 | 0.030 |
Why?
|
| Genes, Dominant | 2 | 2008 | 245 | 0.030 |
Why?
|
| Head Injuries, Closed | 1 | 1996 | 46 | 0.030 |
Why?
|
| Gene Knockout Techniques | 1 | 2016 | 124 | 0.030 |
Why?
|
| Vaccines, Synthetic | 2 | 2010 | 316 | 0.030 |
Why?
|
| Hematopoiesis | 1 | 2018 | 216 | 0.030 |
Why?
|
| Aged, 80 and over | 2 | 2017 | 6603 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 1 | 1996 | 29 | 0.030 |
Why?
|
| Myelodysplastic Syndromes | 2 | 2014 | 138 | 0.030 |
Why?
|
| Membrane Proteins | 1 | 2003 | 1527 | 0.030 |
Why?
|
| Inflammation Mediators | 1 | 2017 | 244 | 0.030 |
Why?
|
| Antibodies | 2 | 2012 | 374 | 0.030 |
Why?
|
| Artifacts | 1 | 1996 | 109 | 0.030 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2000 | 459 | 0.030 |
Why?
|
| Neuroectodermal Tumors | 1 | 2015 | 11 | 0.030 |
Why?
|
| Antigenic Variation | 1 | 1995 | 39 | 0.030 |
Why?
|
| Batch Cell Culture Techniques | 1 | 2014 | 6 | 0.030 |
Why?
|
| Injections, Intralesional | 1 | 2014 | 48 | 0.030 |
Why?
|
| Forms and Records Control | 1 | 2014 | 10 | 0.030 |
Why?
|
| Maximum Tolerated Dose | 1 | 2015 | 163 | 0.030 |
Why?
|
| Culture Media, Serum-Free | 1 | 2014 | 22 | 0.030 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2014 | 23 | 0.030 |
Why?
|
| 5' Untranslated Regions | 1 | 2015 | 58 | 0.030 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2014 | 31 | 0.030 |
Why?
|
| Clone Cells | 2 | 2002 | 166 | 0.030 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2015 | 344 | 0.030 |
Why?
|
| DNA Probes | 1 | 1994 | 123 | 0.030 |
Why?
|
| Aspergillosis | 1 | 2014 | 43 | 0.030 |
Why?
|
| Etanercept | 1 | 2014 | 40 | 0.030 |
Why?
|
| Radiography | 1 | 1996 | 823 | 0.030 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 1 | 1994 | 73 | 0.030 |
Why?
|
| NADPH Oxidase 2 | 1 | 2013 | 40 | 0.030 |
Why?
|
| Kinetics | 2 | 2007 | 1333 | 0.030 |
Why?
|
| Dogs | 1 | 2014 | 775 | 0.030 |
Why?
|
| Species Specificity | 1 | 2014 | 550 | 0.030 |
Why?
|
| Prednisone | 1 | 2014 | 276 | 0.030 |
Why?
|
| Protein Engineering | 1 | 2013 | 73 | 0.030 |
Why?
|
| Predictive Value of Tests | 2 | 2011 | 2174 | 0.030 |
Why?
|
| DNA Repair | 1 | 2016 | 585 | 0.030 |
Why?
|
| CD2 Antigens | 1 | 2012 | 8 | 0.030 |
Why?
|
| Interleukin Receptor Common gamma Subunit | 1 | 2012 | 12 | 0.030 |
Why?
|
| NADPH Oxidases | 1 | 2013 | 114 | 0.030 |
Why?
|
| Drug Resistance | 2 | 2009 | 257 | 0.030 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2013 | 108 | 0.030 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2014 | 84 | 0.030 |
Why?
|
| Restriction Mapping | 2 | 1990 | 189 | 0.030 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2013 | 69 | 0.030 |
Why?
|
| Data Collection | 1 | 2014 | 381 | 0.030 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2013 | 75 | 0.020 |
Why?
|
| Diagnosis, Differential | 2 | 1996 | 1898 | 0.020 |
Why?
|
| Biomarkers | 3 | 2010 | 3091 | 0.020 |
Why?
|
| Antigens, CD | 2 | 2007 | 432 | 0.020 |
Why?
|
| Chimera | 1 | 2012 | 83 | 0.020 |
Why?
|
| Androgen Antagonists | 1 | 2013 | 120 | 0.020 |
Why?
|
| Toxicity Tests | 1 | 2012 | 35 | 0.020 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2014 | 389 | 0.020 |
Why?
|
| Chemokine CXCL10 | 1 | 2012 | 53 | 0.020 |
Why?
|
| Antigens, Tumor-Associated, Carbohydrate | 1 | 2011 | 12 | 0.020 |
Why?
|
| Molecular Weight | 2 | 1989 | 387 | 0.020 |
Why?
|
| Internet | 1 | 2014 | 376 | 0.020 |
Why?
|
| Anti-HIV Agents | 1 | 2015 | 320 | 0.020 |
Why?
|
| Bone Marrow Neoplasms | 1 | 2011 | 23 | 0.020 |
Why?
|
| DNA Damage | 1 | 2015 | 513 | 0.020 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2011 | 63 | 0.020 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2014 | 293 | 0.020 |
Why?
|
| Prospective Studies | 3 | 2007 | 6158 | 0.020 |
Why?
|
| In Situ Hybridization | 1 | 2012 | 471 | 0.020 |
Why?
|
| Immediate-Early Proteins | 1 | 2011 | 58 | 0.020 |
Why?
|
| Japan | 1 | 2011 | 133 | 0.020 |
Why?
|
| Chloramphenicol O-Acetyltransferase | 1 | 1990 | 79 | 0.020 |
Why?
|
| Flagellin | 1 | 2010 | 19 | 0.020 |
Why?
|
| Collateral Circulation | 1 | 1991 | 45 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2014 | 1275 | 0.020 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 1990 | 70 | 0.020 |
Why?
|
| Ischemic Attack, Transient | 1 | 1991 | 58 | 0.020 |
Why?
|
| Melanoma, Experimental | 1 | 2010 | 35 | 0.020 |
Why?
|
| Antigens, Differentiation | 1 | 1990 | 61 | 0.020 |
Why?
|
| CD5 Antigens | 1 | 1990 | 36 | 0.020 |
Why?
|
| Cerebral Angiography | 1 | 1991 | 101 | 0.020 |
Why?
|
| Transplantation | 1 | 2010 | 27 | 0.020 |
Why?
|
| Early Diagnosis | 1 | 2011 | 183 | 0.020 |
Why?
|
| Cloning, Molecular | 1 | 1992 | 897 | 0.020 |
Why?
|
| Human T-lymphotropic virus 1 | 1 | 1990 | 62 | 0.020 |
Why?
|
| Algorithms | 2 | 2008 | 1630 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2012 | 511 | 0.020 |
Why?
|
| Coxsackie and Adenovirus Receptor-Like Membrane Protein | 1 | 2010 | 13 | 0.020 |
Why?
|
| Immunization, Secondary | 1 | 2010 | 104 | 0.020 |
Why?
|
| Chemokine CCL2 | 1 | 2010 | 122 | 0.020 |
Why?
|
| Pyrroles | 1 | 2011 | 183 | 0.020 |
Why?
|
| Blood Cells | 1 | 2010 | 50 | 0.020 |
Why?
|
| United States Food and Drug Administration | 1 | 2010 | 151 | 0.020 |
Why?
|
| Deoxycytidine | 1 | 2010 | 78 | 0.020 |
Why?
|
| T Cell Transcription Factor 1 | 1 | 2009 | 3 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2012 | 794 | 0.020 |
Why?
|
| Transcription Initiation Site | 1 | 2009 | 32 | 0.020 |
Why?
|
| Mutagenicity Tests | 1 | 2009 | 36 | 0.020 |
Why?
|
| Transcription, Genetic | 3 | 1990 | 1699 | 0.020 |
Why?
|
| Ribosomal Protein S6 Kinases | 1 | 2009 | 50 | 0.020 |
Why?
|
| Lymphoid Enhancer-Binding Factor 1 | 1 | 2009 | 12 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2014 | 1180 | 0.020 |
Why?
|
| Electric Stimulation | 1 | 1990 | 326 | 0.020 |
Why?
|
| Chemokine CCL22 | 1 | 2009 | 6 | 0.020 |
Why?
|
| Carotid Artery Diseases | 1 | 1991 | 148 | 0.020 |
Why?
|
| DNA, Recombinant | 1 | 1989 | 105 | 0.020 |
Why?
|
| Chemokine CCL17 | 1 | 2009 | 9 | 0.020 |
Why?
|
| Reed-Sternberg Cells | 1 | 2009 | 7 | 0.020 |
Why?
|
| Receptors, Lymphocyte Homing | 1 | 2009 | 20 | 0.020 |
Why?
|
| Defective Viruses | 1 | 1989 | 18 | 0.020 |
Why?
|
| Deoxyribonuclease EcoRI | 1 | 1988 | 6 | 0.020 |
Why?
|
| Contracts | 1 | 2008 | 9 | 0.020 |
Why?
|
| Congresses as Topic | 1 | 2010 | 175 | 0.020 |
Why?
|
| RNA, Viral | 1 | 2011 | 536 | 0.020 |
Why?
|
| Stromal Cells | 1 | 2010 | 302 | 0.020 |
Why?
|
| Pyrimidines | 1 | 2011 | 374 | 0.020 |
Why?
|
| Retrospective Studies | 2 | 2022 | 16360 | 0.020 |
Why?
|
| Genetic Variation | 1 | 1995 | 1502 | 0.020 |
Why?
|
| CpG Islands | 1 | 2009 | 323 | 0.020 |
Why?
|
| Th2 Cells | 1 | 2009 | 186 | 0.020 |
Why?
|
| RNA, Neoplasm | 1 | 2008 | 138 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2017 | 4818 | 0.020 |
Why?
|
| Simian virus 40 | 1 | 1988 | 199 | 0.020 |
Why?
|
| Education, Medical, Continuing | 1 | 2008 | 141 | 0.020 |
Why?
|
| Immunoglobulin Isotypes | 1 | 2007 | 15 | 0.020 |
Why?
|
| Reoperation | 1 | 1991 | 833 | 0.020 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2009 | 358 | 0.020 |
Why?
|
| Histocompatibility Antigens | 1 | 2007 | 19 | 0.020 |
Why?
|
| Protein Kinases | 1 | 1989 | 330 | 0.020 |
Why?
|
| Lipopolysaccharide Receptors | 1 | 2007 | 51 | 0.020 |
Why?
|
| Substrate Specificity | 1 | 2007 | 295 | 0.020 |
Why?
|
| Immunoglobulin lambda-Chains | 1 | 2006 | 11 | 0.020 |
Why?
|
| Neprilysin | 1 | 1986 | 19 | 0.020 |
Why?
|
| Saccharomyces cerevisiae Proteins | 1 | 1989 | 277 | 0.020 |
Why?
|
| Epigenesis, Genetic | 1 | 2011 | 678 | 0.020 |
Why?
|
| Severe Combined Immunodeficiency | 1 | 2007 | 106 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 1998 | 2433 | 0.020 |
Why?
|
| Mothers | 1 | 2009 | 355 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2009 | 1243 | 0.020 |
Why?
|
| Lymphocyte Function-Associated Antigen-1 | 1 | 1985 | 30 | 0.020 |
Why?
|
| Adenosine Triphosphate | 1 | 2006 | 282 | 0.020 |
Why?
|
| 3' Untranslated Regions | 1 | 2006 | 163 | 0.020 |
Why?
|
| Proto-Oncogene Proteins | 1 | 1989 | 547 | 0.020 |
Why?
|
| Dimerization | 1 | 2005 | 144 | 0.010 |
Why?
|
| Mucopolysaccharidosis I | 1 | 2004 | 7 | 0.010 |
Why?
|
| Postoperative Period | 1 | 1986 | 334 | 0.010 |
Why?
|
| Virulence | 1 | 2005 | 264 | 0.010 |
Why?
|
| Antigen-Antibody Reactions | 1 | 2004 | 60 | 0.010 |
Why?
|
| Sialic Acids | 1 | 1984 | 20 | 0.010 |
Why?
|
| Hydroxyurea | 1 | 2004 | 82 | 0.010 |
Why?
|
| Cold Temperature | 1 | 1984 | 78 | 0.010 |
Why?
|
| Neuraminidase | 1 | 1984 | 36 | 0.010 |
Why?
|
| beta-Galactosidase | 1 | 1984 | 147 | 0.010 |
Why?
|
| Serrate-Jagged Proteins | 1 | 2003 | 38 | 0.010 |
Why?
|
| ABO Blood-Group System | 1 | 1984 | 66 | 0.010 |
Why?
|
| Jagged-1 Protein | 1 | 2003 | 52 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2015 | 3583 | 0.010 |
Why?
|
| Insecta | 1 | 2003 | 58 | 0.010 |
Why?
|
| Immunotoxins | 1 | 2003 | 21 | 0.010 |
Why?
|
| Feces | 1 | 2007 | 727 | 0.010 |
Why?
|
| Gene Targeting | 1 | 2004 | 177 | 0.010 |
Why?
|
| HLA-DP beta-Chains | 1 | 2002 | 9 | 0.010 |
Why?
|
| Urine | 1 | 2003 | 90 | 0.010 |
Why?
|
| Cell Membrane | 1 | 1985 | 462 | 0.010 |
Why?
|
| Erythrocytes | 1 | 1984 | 219 | 0.010 |
Why?
|
| Polymorphism, Genetic | 1 | 2006 | 816 | 0.010 |
Why?
|
| Protein Binding | 1 | 2007 | 1756 | 0.010 |
Why?
|
| Saliva | 1 | 2003 | 114 | 0.010 |
Why?
|
| Cell Nucleus | 1 | 1985 | 676 | 0.010 |
Why?
|
| Homeostasis | 1 | 2007 | 703 | 0.010 |
Why?
|
| Rats | 1 | 2009 | 3727 | 0.010 |
Why?
|
| Smad2 Protein | 1 | 2002 | 49 | 0.010 |
Why?
|
| Genome-Wide Association Study | 1 | 2009 | 1689 | 0.010 |
Why?
|
| Immunoglobulin Fragments | 1 | 2002 | 13 | 0.010 |
Why?
|
| Calcium-Binding Proteins | 1 | 2003 | 326 | 0.010 |
Why?
|
| Receptors, Fc | 1 | 2002 | 29 | 0.010 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2003 | 282 | 0.010 |
Why?
|
| Antibodies, Neoplasm | 1 | 2002 | 60 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2011 | 3465 | 0.010 |
Why?
|
| Lymphocyte Culture Test, Mixed | 1 | 2001 | 41 | 0.010 |
Why?
|
| Receptors, Notch | 1 | 2003 | 201 | 0.010 |
Why?
|
| Models, Immunological | 1 | 2001 | 36 | 0.010 |
Why?
|
| Seasons | 1 | 2003 | 312 | 0.010 |
Why?
|
| Hepatitis B e Antigens | 1 | 2000 | 12 | 0.010 |
Why?
|
| Nucleocapsid | 1 | 2000 | 7 | 0.010 |
Why?
|
| Hepatitis B Core Antigens | 1 | 2000 | 15 | 0.010 |
Why?
|
| Injections, Intraperitoneal | 1 | 2000 | 75 | 0.010 |
Why?
|
| Immunoglobulin Fc Fragments | 1 | 2000 | 30 | 0.010 |
Why?
|
| Adjuvants, Immunologic | 1 | 2002 | 382 | 0.010 |
Why?
|
| Alu Elements | 1 | 2000 | 65 | 0.010 |
Why?
|
| Hepatitis B virus | 1 | 2000 | 130 | 0.010 |
Why?
|
| CD40 Antigens | 1 | 1999 | 26 | 0.010 |
Why?
|
| Sequence Homology, Nucleic Acid | 2 | 1990 | 289 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2003 | 1327 | 0.010 |
Why?
|
| Transcription Factors | 1 | 1989 | 2593 | 0.010 |
Why?
|
| Injections, Intravenous | 1 | 1998 | 249 | 0.010 |
Why?
|
| Precipitin Tests | 1 | 1997 | 155 | 0.010 |
Why?
|
| Drug Resistance, Microbial | 1 | 1998 | 194 | 0.010 |
Why?
|
| CHO Cells | 1 | 1997 | 169 | 0.010 |
Why?
|
| Neutralization Tests | 1 | 1997 | 235 | 0.010 |
Why?
|
| Cricetinae | 1 | 1997 | 422 | 0.010 |
Why?
|
| Nuclear Family | 1 | 1996 | 49 | 0.010 |
Why?
|
| Histocompatibility | 1 | 1996 | 47 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2006 | 3158 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 1997 | 684 | 0.010 |
Why?
|
| Infant, Newborn | 2 | 2004 | 8236 | 0.010 |
Why?
|
| Mycoses | 1 | 1996 | 118 | 0.010 |
Why?
|
| Kanamycin Kinase | 1 | 1994 | 16 | 0.010 |
Why?
|
| Moloney murine leukemia virus | 1 | 1994 | 19 | 0.010 |
Why?
|
| Monitoring, Physiologic | 1 | 1995 | 377 | 0.010 |
Why?
|
| Skin Neoplasms | 1 | 2000 | 862 | 0.010 |
Why?
|
| Bacterial Infections | 1 | 1996 | 308 | 0.010 |
Why?
|
| Clinical Protocols | 1 | 1994 | 240 | 0.010 |
Why?
|
| Brain | 1 | 2004 | 3004 | 0.010 |
Why?
|
| Informed Consent | 1 | 1994 | 333 | 0.010 |
Why?
|
| Nucleotide Mapping | 1 | 1990 | 17 | 0.010 |
Why?
|
| Oligonucleotide Probes | 1 | 1990 | 85 | 0.010 |
Why?
|
| Butyrates | 1 | 1989 | 35 | 0.000 |
Why?
|
| Gene Products, tat | 1 | 1989 | 28 | 0.000 |
Why?
|
| Proto-Oncogene Proteins c-jun | 1 | 1989 | 39 | 0.000 |
Why?
|
| Proto-Oncogene Proteins c-fos | 1 | 1989 | 61 | 0.000 |
Why?
|
| Fungal Proteins | 1 | 1989 | 134 | 0.000 |
Why?
|
| Protein Biosynthesis | 1 | 1990 | 663 | 0.000 |
Why?
|
| Receptors, Complement 3d | 1 | 1986 | 6 | 0.000 |
Why?
|
| Incidence | 1 | 1994 | 3148 | 0.000 |
Why?
|
| Binding Sites | 1 | 1989 | 1303 | 0.000 |
Why?
|
| New Guinea | 1 | 1985 | 3 | 0.000 |
Why?
|
| Africa | 1 | 1985 | 133 | 0.000 |
Why?
|
| Karyotyping | 1 | 1985 | 323 | 0.000 |
Why?
|